Jump to Navigation

The Aethlon ADAPT™ System

The Aethlon ADAPT™ system is an adaptive dialysis-like affinity platform technology that provides the foundation for an entirely new class of therapeutics that target the selective clearance of harmful agents from the entire circulatory system.  Therapies that evolve from the Aethlon ADAPT™ system overcome the historic limitation of extracorporeal strategies that indiscriminately adsorb or remove particles solely by molecule size.  In function, our device platform allows the immobilization of single or multiple affinity drug agents in the outer-capillary space of plasma membrane technologies as a means to provide rapid real-time clearance of corresponding targets without adding drug toxicity or interaction risks to established therapies.  Beyond providing a novel regulatory and commercialization pathway for affinity drug agents, Aethlon ADAPT™ therapies can be implemented for use within the global infrastructure of dialysis machines and CRRT systems already located in hospitals and clinics.  

At present, the Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a $6.8 million contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians.  As we advance our current pipeline of therapies toward market, we plan to further leverage our ADAPT™ system to generate new revenue sources through future government contracts or grants, and collaborations with organizations representing the pharmaceutical, biotechnology and medical device industry.

Site 'Subpage' Navigation:

Product Pipeline

Back to Top